Evidence map›Paper›PMID 36559162›Full record

ArticlePharmaceutics2022

CuS-

Yanna Cui, Hui Yan, Haoze Wang, Yongming Zhang, Meng Li, Kai Cui, Zeyu Xiao, Liu Liu, Wenhui Xie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yanna CuiDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0001-7690-627X
Hui YanDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Haoze WangDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Yongming ZhangDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Meng LiDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Kai CuiDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zeyu XiaoDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Liu LiuDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0002-8983-4137
Wenhui XieDepartment of Nuclear Medicine, Shanghai Chest Hospital & Department of Pharmacology and Chemical Biology, Translational Medicine Collaborative Innovation Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Jiao Tong University · CN

Funding

National Key Research and Development Program of China 2020YFA0210800National Natural Science Foundation of China 21874092, 52161160307, 31671003, and 82272044Natural Science Foundation of Shanghai 21ZR1458900Startup Fund for Young Faculty at Shanghai Jiao Tong University 21X010501069the basic research of Shanghai Chest Hospital 2020YNJCM07Youth Medical Talents-Medical Imaging Practitioners Program SHWRS(2020)_087
6 · The paper itself

Abstract

Brachytherapy is one mainstay treatment for lung cancer. However, a great challenge in brachytherapy is radio-resistance, which is caused by severe hypoxia in solid tumors. In this research, we have developed a PEGylated

Indexed as

brachytherapymultiple mild-hyperthermiaPEGylated nanotheranosticsradio-resistancetumor hypoxia

Identifiers

PMID36559162
PMCPMC9785376
OpenAlexW4310398256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.